Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00087451
Status:
COMPLETED
Last Update Posted:
2015-08-19
First Post:
2004-07-08
Brief Title:
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma 8669-023COMPLETED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase I Sequential Ascending Dose Trial of AP23573 in Patients With Progressive or Recurrent Malignant Glioma
Status:
COMPLETED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase I open-label non-randomized sequential dose escalation cohort trial of the safety tolerability and maximum tolerated dose MTD of AP23573 when administered intravenously as a 30-minute infusion once daily for five days repeated every two weeks to patients with progressive or recurrent malignant glioma
Detailed Description:
The primary objective of the study is to determine the safety tolerability and maximum tolerated dose MTD of AP23573 when administered intravenously once daily for five days repeated every two weeks to patients with progressive or recurrent gliomas who have failed standard therapy and who are or are not receiving enzyme-inducing anticonvulsant EIAC medications
The secondary objectives are to characterize the pharmacokinetic profile of AP23573 when administered daily for five days repeated every two weeks at the indicated dosage levels in patients receiving and not receiving EIAC describe the progression-free survival at six months describe changes in proteins affected by mTOR inhibition describe single timepoint status of proteins affected by mTOR inhibition in tumor tissue surgical specimens after AP23573 dosing describe the status of key proteins in the mTOR signaling pathway in archival tumor samples if available describe health-related quality of life at the start of the trial and prior to study drug infusion and at various timepoints throughout the trial
Protocol Outline
This is a Phase I open-label non-randomized sequential dose escalation cohort trial of the safety tolerability and MTD of AP23573 when administered intravenously as a 30-minute infusion once daily for five days repeated every two weeks to patients with progressive or recurrent malignant glioma
The secondary objectives are to characterize the pharmacokinetic profile of AP23573 when administered daily for five days repeated every two weeks at the indicated dosage levels in patients receiving and not receiving EIAC describe the progression-free survival at six months describe changes in proteins affected by mTOR inhibition describe single timepoint status of proteins affected by mTOR inhibition in tumor tissue surgical specimens after AP23573 dosing describe the status of key proteins in the mTOR signaling pathway in archival tumor samples if available describe health-related quality of life at the start of the trial and prior to study drug infusion and at various timepoints throughout the trial
Protocol Outline
This is a Phase I open-label non-randomized sequential dose escalation cohort trial of the safety tolerability and MTD of AP23573 when administered intravenously as a 30-minute infusion once daily for five days repeated every two weeks to patients with progressive or recurrent malignant glioma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AP23573-04-103 | None | None | None |